Abstract
Rare genetic diseases impact many people worldwide and are challenging to diagnose. In this study, we introduce a novel regional population cohort approach to identify pathogenic variants that occur more frequently within specific populations and are of clinical interest. We utilized a cohort from Quebec, including the Saguenay-Lac-Saint-Jean region, which is known for its founder effect and higher frequency of certain pathogenic variants. By analyzing both the frequency of these variants and their origin through shared identical-by-descent segments, we validated 38 variants previously reported as being more common due to the founder effect. Additionally, we identified 42 unreported founder variants in Quebec or the Saguenay-Lac-Saint-Jean, some with carrier rates estimates as high as 1/22. We also observed a greater deleterious mutational load for the studied variants in individuals from the Saguenay-Lac-Saint-Jean compared to other urban Quebec regions. These findings were brought to the clinic where 12 pathogenic variants were detected in patients, including 3 that are responsible for very severe diseases and could be considered for inclusion in a carrier test for the Saguenay-Lac-Saint-Jean population. This study highlights the potential underestimation of rare disease prevalence and presents a population-based approach that could aid clinicians in their diagnostic efforts and patients' management.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Funding for SLG was provided by the Canada Research Chair in Genetics and Genealogy. LB and CG were funded by the Research Chair in Génétique et parcours de vie en santé.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the University of Quebec in Chicoutimi (UQAC) ethics board. The approval for the secondary use of anonymized samples coming from the provincial screening testing was obtained from the Centre intégré universitaire de santé et de services sociaux (CIUSSS) du Saguenay-Lac-Saint-Jean (SLSJ) Direction of professional services. Written informed consent for the use of saliva samples were obtained from participants.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Quebec genotype, imputed and WGS data are available via an independent data access committee by the CARTaGENE cohort.
